# Athira Pharma Inc. (ATHA)

Source: https://www.quantisnow.com/company/ATHA
Generated: 2026-11-12T09:37:59.809Z

- Ticker: ATHA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2020
- Website: athira.com

## About

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

## Latest ATHA news and filings

- 2026-01-16 21:46 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-athira-pharma-inc-6352464)
- 2026-01-09 21:05 UTC [SEC Form 8-K] [Athira Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athira-pharma-inc-filed-sec-form-8-k-amendments-to-articles-6344338)
- 2026-01-09 12:00 UTC [Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA"](https://www.quantisnow.com/insight/athira-pharma-announces-name-change-to-leonabio-inc-with-new-6343787)
- 2026-01-06 00:52 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER San Martin Javier converted options into 4,667 shares and sold $11,311 worth of shares (1,644 units at $6.88), increasing direct ownership by 42% to 10,189 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-san-martin-javier-converted-options-into-4667-6336720)
- 2026-01-06 00:51 UTC [SEC Form 4] [President and CEO Litton Mark James sold $17,792 worth of shares (2,586 units at $6.88) and converted options into 10,834 shares, increasing direct ownership by 25% to 40,828 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-litton-mark-james-sold-17792-worth-of-6336719)
- 2026-01-06 00:50 UTC [SEC Form 4] [Chief Financial Officer Renninger Robert was granted 1,000 shares, converted options into 1,236 shares and sold $2,043 worth of shares (297 units at $6.88), increasing direct ownership by 18% to 12,857 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-renninger-robert-was-granted-1000-shares-converted-6336718)
- 2026-01-06 00:50 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Church Kevin was granted 1,000 shares, converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 22% to 20,681 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-church-kevin-was-granted-1000-shares-converted-6336715)
- 2026-01-06 00:49 UTC [SEC Form 4] [General Counsel and CCO Worthington Mark converted options into 3,667 shares and sold $6,027 worth of shares (876 units at $6.88), increasing direct ownership by 25% to 13,978 units (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-and-cco-worthington-mark-converted-options-into-3667-6336714)
- 2025-12-29 21:19 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Renninger Robert](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-renninger-robert-6328647)
- 2025-12-29 21:17 UTC [SEC Form 4] [SEC Form 4 filed by President and CEO Litton Mark James](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-and-ceo-litton-mark-6328639)
- 2025-12-29 21:15 UTC [SEC Form 4] [SEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Church Kevin](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-church-kevin-6328622)
- 2025-12-29 21:14 UTC [SEC Form 4] [SEC Form 4 filed by CHIEF MEDICAL OFFICER San Martin Javier](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-medical-officer-san-martin-6328571)
- 2025-12-29 21:12 UTC [SEC Form 4] [SEC Form 4 filed by General Counsel and CCO Worthington Mark](https://www.quantisnow.com/insight/sec-form-4-filed-by-general-counsel-and-cco-worthington-6328556)
- 2025-12-23 22:16 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-athira-pharma-inc-6327188)
- 2025-12-23 22:12 UTC [SEC Form 4] [Director Perceptive Advisors Llc was granted 1,319,026 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-perceptive-advisors-llc-was-granted-1319026-shares-sec-form-6327160)
- 2025-12-22 21:30 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-athira-pharma-inc-6325523)
- 2025-12-18 20:47 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-athira-pharma-inc-6321927)
- 2025-12-18 13:24 UTC [SEC Form 8-K] [Amendment: Athira Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-athira-pharma-inc-filed-sec-form-8-k-entry-into-6321364)
- 2025-12-18 12:16 UTC [SEC Form 8-K] [Athira Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athira-pharma-inc-filed-sec-form-8-k-entry-into-a-6321209)
- 2025-12-18 12:02 UTC [Earnings Date] [Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million](https://www.quantisnow.com/insight/athira-pharma-announces-exclusive-license-to-lasofoxifene-phase-3-development-6321193)
- 2025-11-06 21:13 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-athira-pharma-inc-6265750)
- 2025-11-06 21:09 UTC [SEC Form 8-K] [Athira Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athira-pharma-inc-filed-sec-form-8-k-results-of-operations-6265601)
- 2025-11-06 21:05 UTC [Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/athira-pharma-reports-third-quarter-2025-financial-results-and-provides-6265245)
- 2025-10-10 20:41 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-athira-pharma-inc-6230175)
- 2025-10-03 13:11 UTC [SEC Form 8-K] [Athira Pharma Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/athira-pharma-inc-filed-sec-form-8-k-other-events-6221865)
- 2025-09-11 13:00 UTC [SEC Form 8-K] [Athira Pharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athira-pharma-inc-filed-sec-form-8-k-material-modification-to-6197543)
- 2025-09-11 13:00 UTC [Athira Pharma Announces Reverse Stock Split](https://www.quantisnow.com/insight/athira-pharma-announces-reverse-stock-split-6197516)
- 2025-08-14 11:00 UTC [Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025](https://www.quantisnow.com/insight/athira-pharma-presents-ath-1105-phase-1-trial-results-at-als-6164326)
- 2025-08-07 20:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-athira-pharma-inc-6153943)
- 2025-08-07 20:11 UTC [SEC Form 8-K] [Athira Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/athira-pharma-inc-filed-sec-form-8-k-results-of-operations-6153761)
- 2025-08-07 20:05 UTC [Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/athira-pharma-reports-second-quarter-2025-financial-results-and-provides-6153502)
- 2025-07-02 20:35 UTC [SEC Form 4] [CHIEF SCIENTIFIC OFFICER Church Kevin was granted 10,000 shares, converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 29% to 168,901 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-church-kevin-was-granted-10000-shares-converted-6108837)
- 2025-07-02 20:34 UTC [SEC Form 4] [President and CEO Litton Mark James converted options into 108,334 shares and sold $7,374 worth of shares (25,123 units at $0.29), increasing direct ownership by 34% to 325,802 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-litton-mark-james-converted-options-into-108334-6108831)
- 2025-07-02 20:33 UTC [SEC Form 4] [CHIEF MEDICAL OFFICER San Martin Javier converted options into 46,666 shares and sold $3,182 worth of shares (10,842 units at $0.29), increasing direct ownership by 100% to 71,665 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-san-martin-javier-converted-options-into-46666-6108823)
- 2025-07-02 20:33 UTC [SEC Form 4] [General Counsel and CCO Worthington Mark converted options into 36,666 shares and sold $2,502 worth of shares (8,526 units at $0.29), increasing direct ownership by 34% to 111,875 units (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-and-cco-worthington-mark-converted-options-into-36666-6108805)
- 2025-07-02 20:32 UTC [SEC Form 4] [SVP, Finance and Accounting Renninger Robert converted options into 12,359 shares, sold $850 worth of shares (2,897 units at $0.29) and was granted 10,000 shares, increasing direct ownership by 22% to 109,186 units (SEC Form 4)](https://www.quantisnow.com/insight/svp-finance-and-accounting-renninger-robert-converted-options-into-12359-6108790)
- 2025-07-01 23:37 UTC [SEC Form 144] [SEC Form 144 filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-athira-pharma-inc-6106815)
- 2025-07-01 23:36 UTC [SEC Form 144] [SEC Form 144 filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-athira-pharma-inc-6106814)
- 2025-07-01 23:33 UTC [SEC Form 144] [SEC Form 144 filed by Athira Pharma Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-athira-pharma-inc-6106811)
- 2025-06-03 21:37 UTC [SEC Form 4] [SEC Form 4 filed by Director Fluke John M Jr](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fluke-john-m-jr-6070917)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ATHA
- Earnings history: https://www.quantisnow.com/earnings/ATHA
- Dividend history: https://www.quantisnow.com/dividends/ATHA
- Insider transactions: https://www.quantisnow.com/insiders/ATHA
- Options chain: https://www.quantisnow.com/options/ATHA
- SEC 8-K filings only: https://www.quantisnow.com/company/ATHA/8-k
- RSS and alerts for ATHA: https://www.quantisnow.com/docs/rss-feeds.md